

09 - References

References

796 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 9 References

1. Martínez-González L, et al. Incidence of anorexia nervosa in women: a systematic review and meta-analysis. *Int J Environ Res Public Health* 2020; 17:3824.
2. Galmiche M, et al. Prevalence of eating disorders over the 2000–2018 period: a systematic literature review. *Am J Clin Nutr* 2019; 109:1402–1413.
3. Nitsch A, et al. Medical complications of bulimia nervosa. *Cleve Clin J Med* 2021; 88:333–343.
4. Chiappini S, et al. Exploring the nexus of binge eating disorder (BED), new psychoactive substances (NPS), and misuse of pharmaceuticals: charting a path forward. *Expert Opin Pharmacother* 2023; 24:1915–1918.
5. Frank GKW. Pharmacotherapeutic strategies for the treatment of anorexia nervosa – too much for one drug? *Expert Opin Pharmacother* 2020; 21:1045–1058.
6. National Institute for Health and Care Excellence. Eating disorders: recognition and treatment. NICE Guideline [NG69]. 2017 (last updated March 2020); <https://www.nice.org.uk/guidance/ng69>.
7. American Psychiatric Association. Treatment of patients with eating disorders, third edition. *Am J Psychiatry* 2006; 163:4–54.
8. Frank B, et al. Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents. *J Eat Disord* 2023; 11:151.
9. Costandache GI, et al. An overview of the treatment of eating disorders in adults and adolescents: pharmacology and psychotherapy. *Postep Psychiatr Neurol* 2023; 32:40–48.
10. Bauschka M, et al. Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study. *J Eat Disord* 2023; 11:215.
11. Thorey S, et al. Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: a systematic scoping review. *PLoS One* 2023; 18:e0278189.
12. Bissada H, et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2008; 165:1281–1288.
13. Tahillioğlu A, et al. Is aripiprazole a key to unlock anorexia nervosa? A case series. *Clin Case Rep* 2020; 8:2827–2834.
14. Frank GK, et al. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. *Int J Eat Disord* 2017; 50:447–450.

15. Himmerich H, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. *World J Biol Psychiatry* 2023; 1-64.
16. Court A, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. *J Psychiatr Res* 2010; 44:-1027-1034.
17. Powers PS, et al. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. *Eur Eat Disord Rev* 2012; 20:331-334.
18. Naguy A, et al. An adolescent male with anorexia nervosa favorably responded to mirtazapine. *Am J Ther* 2018; 25:e675-e676.
19. Safer DL, et al. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report. *Int J Eat Disord* 2011; 44:178-181.
20. Hrdlicka M, et al. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study. *Eur Child Adolesc Psychiatry* 2008; 17:187-189.
21. Andries A, et al. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. *Int J Eat Disord* 2014; 47:18-23.
22. Claudino AM, et al. Antidepressants for anorexia nervosa. *Cochrane Database Syst Rev* 2006; 1:CD004365.
23. Barbarich NC, et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. *Int J Eat Disord* 2004; 35:10-15.
24. Rossi G, et al. Pharmacological treatment of anorexia nervosa: a retrospective study in preadolescents and adolescents. *Clin Pediatr (Phila)* 2007; 46:806-811.
25. Keeler JL, et al. Ketamine as a treatment for anorexia nervosa: a narrative review. *Nutrients* 2021; 13:4158.
26. Keeler JL, et al. Case report: intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa. *Front Psychiatry* 2023; 14:1181447.
27. Keeler JL, et al. Novel treatments for anorexia nervosa: insights from neuroplasticity research. *Eur Eat Disord Rev* 2024; 32:1069-1084.
28. Quagebeur R, et al. The role of short-chain fatty acids (SCFAs) in regulating stress responses, eating behavior, and nutritional state in anorexia nervosa: protocol for a randomized controlled trial. *J Eat Disord* 2023; 11:191.
29. Nagata JM, et al. Assessment of vitamin D among male adolescents and young adults hospitalized with eating disorders. *J Eat Disord* 2022; 10:104.
30. Royal College of Psychiatrists. Medical emergencies in eating disorders (MEED). Guidance on recognition and management. College Report [CR233]. 2022; <https://www.rcpsych.ac.uk/improving-care/campaigning-for-better-mental-health--policy/college-reports/2022-collegereports/cr233>.
31. Marvanova M, et al. Role of antidepressants in the treatment of adults with anorexia nervosa. *Ment Health Clin* 2018; 8:127-137.
32. Walsh BT, et al. Time course of relapse following acute treatment for anorexia nervosa. *Am J Psychiatry* 2021; 178:848-853.
33. Himmerich H, et al. Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. *Pharmacol Ther* 2020; 217:107667.

34. Bacaltchuk J, et al. Antidepressants versus placebo for people with bulimia nervosa. *Cochrane Database Syst Rev* 2003; 4:CD003391.
35. Ghaderi A, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. *Peer J* 2018; 6:e51113.
36. Sysko R, et al. Early response to antidepressant treatment in bulimia nervosa. *Psychol Med* 2010; 40:999-1005.

Drug treatment of other psychiatric conditions CHAPTER 9

37. McElroy SL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. *Int J Eat Disord* 2011; 44:81-90.
38. Hilbert A, et al. Meta-analysis on the long-term effectiveness of psychological and medical treatments for binge-eating disorder. *Int J Eat Disord* 2020; 53:1353-1376.
39. McElroy SL, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. *JAMA Psychiatry* 2015; 72:235-246.
40. Citrome L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2015; 69:410-421.
41. Grilo CM, et al. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. *CNS Spectr* 2021; 26:481-490.
42. Leombruni P, et al. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. *Adv Ther* 2006; 23:481-494.
43. Leombruni P, et al. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. *Hum Psychopharmacol* 2006; 21:181-188.

Revision #1

Created 2026-01-04 20:17:26 UTC by Omar Ayman

Updated 2026-01-04 20:17:26 UTC by Omar Ayman